ANGN Stock Overview
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.21|
|52 Week High||US$26.30|
|52 Week Low||US$2.15|
|1 Month Change||-18.15%|
|3 Month Change||-74.21%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-87.02%|
Recent News & Updates
|ANGN||US Pharmaceuticals||US Market|
Return vs Industry: Insufficient data to determine how ANGN performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ANGN performed against the US Market.
|ANGN Average Weekly Movement||20.6%|
|Pharmaceuticals Industry Average Movement||10.6%|
|Market Average Movement||6.6%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: ANGN is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 21% a week.
Volatility Over Time: ANGN's weekly volatility has increased from 15% to 21% over the past year.
About the Company
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company’s lead product candidate is ANG-3777, a hepatocyte growth factor mimetic for acute kidney injury, acute lung injury, acute respiratory distress syndrome, central nervous system injuries, and heart injuries. It also develops ANG-3070, a tyrosine kinase inhibitor and rho kinase 2 inhibitors for fibrotic diseases; and CYP11B2, an aldosterone synthase inhibitor for aldosterone-related fibrotic diseases.
Angion Biomedica Fundamentals Summary
|ANGN fundamental statistics|
Is ANGN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ANGN income statement (TTM)|
|Cost of Revenue||US$49.74m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-3.28|
|Net Profit Margin||-3,474.84%|
How did ANGN perform over the long term?See historical performance and comparison
Is Angion Biomedica undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ANGN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ANGN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ANGN is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: ANGN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ANGN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ANGN is good value based on its PB Ratio (1x) compared to the US Pharmaceuticals industry average (2.2x).
How is Angion Biomedica forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if ANGN's forecast earnings growth is above the savings rate (2%).
Earnings vs Market: Insufficient data to determine if ANGN's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ANGN's revenue (55.7% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: ANGN's revenue (55.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ANGN's Return on Equity is forecast to be high in 3 years time
How has Angion Biomedica performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: ANGN is currently unprofitable.
Growing Profit Margin: ANGN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ANGN's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare ANGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ANGN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).
Return on Equity
High ROE: ANGN has a negative Return on Equity (-152.43%), as it is currently unprofitable.
How is Angion Biomedica's financial position?
Financial Position Analysis
Short Term Liabilities: ANGN's short term assets ($104.4M) exceed its short term liabilities ($17.9M).
Long Term Liabilities: ANGN's short term assets ($104.4M) exceed its long term liabilities ($27.5M).
Debt to Equity History and Analysis
Debt Level: ANGN is debt free.
Reducing Debt: ANGN had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ANGN has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ANGN has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 16.9% each year.
What is Angion Biomedica current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ANGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ANGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ANGN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ANGN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ANGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jay Venkatesan (49 yo)
Dr. Jay R. Venkatesan, Ph D., M.D. MBA., is President at Angion Biomedica Corp. since January 2019 and has been its Chief Executive Officer & Director since May 2018. Dr. Venkatesan has been a Non-Employee...
CEO Compensation Analysis
Compensation vs Market: Jay's total compensation ($USD553.23K) is about average for companies of similar size in the US market ($USD582.48K).
Compensation vs Earnings: Jay's compensation has been consistent with company performance over the past year.
Experienced Management: ANGN's management team is considered experienced (2.7 years average tenure).
Experienced Board: ANGN's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ANGN insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: ANGN only recently listed within the past 12 months.
Angion Biomedica Corp.'s employee growth, exchange listings and data sources
- Name: Angion Biomedica Corp.
- Ticker: ANGN
- Exchange: NasdaqGS
- Founded: 1998
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$66.204m
- Shares outstanding: 29.96m
- Website: https://www.angion.com
Number of Employees
- Angion Biomedica Corp.
- 51 Charles Lindbergh Boulevard
- New York
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/21 00:09|
|End of Day Share Price||2022/01/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.